To understand the current status of the application of sacubitril valsartan in hypertensive patients in China and evaluate its rationality in clinical application.
Through the prescription review system of the clinical pharmacy intelligent platform, all outpatient prescriptions with hypertension diagnosed and Sacubitril Valsartan used during the period from June 1 2021 to June 30 2022 were extracted, and the collected data were statistically and analyzed.
A total of 17 100 qualified prescriptions were extracted. The top three departments in the number of prescriptions were hypertension department, cardiology department and nephrology department. Hypertension combined diseases were mainly cardiac insufficiency and renal insufficiency. Through the initial system screen and manual review, 1 033 unreasonable prescriptions were found, accounting for 6.04% of the total number of prescriptions. The main unreasonable problems were repeated drugs and the unreasonable use of combined drugs.
The population of application of Sacubitril Valsartan in hypertensive patients is increasing day by day, but the rationality of medication needs to be further improved. Pharmacists should strengthen the publicity and education of rational medication for doctors and patients to ensure the safety and effectiveness of new antihypertensive drugs in clinical application.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |